dabigatran versus placebo | |||
REDEEM, 2009 NCT00621855 | dabigatran 4 dosages (50mg twice daily, 75mg twice daily, 110mg twice daily, 150mg twice daily) versus placebo | patients with recent acute coronary syndromes (ST- or non-ST-elevation myocardical infarction) | double blind Follow-up duration: 6 months |
in first
in second